Tomografía por emisión de positrones

1. Bender H, Bangard N, Metten N, Bangard M, Mezger J, Schomburg A, Biersack HJ. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. Hybridoma 1999;18:87-91.

2. Goldberg MA, Mayo SW, Papanicolaou N, Fischman AJ, Lee MJ. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997;52:510-515.

3. Bachor R, Kotzerke J, Gottfried HW, Brandle E, Reske SN, Hautmann R. Positron emission tomography (PET) for diagnosis of renal cell carcinoma (RCC). Urologe-Ausgabe-A 1996;35:146-150.

4. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 1997;24:615-620.

5. Bachor R, Kotzerke J, Reske SN, Hautmann R. [Lymph node staging of bladder neck carcinoma with positron emission tomography]. Urologe A 1999;38:46-50.

6. Tomografía por emisión de positrones (PET) con 18FDG en oncología clínica (Revisión Sistemática. AETS noviembre / 2001;125.

7. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001, jan.; 57(1):108-11. 57:108-111.

8. Heicappell R, Muller-Mattheis V, Reinhardt M, Vosberg H, Gerharz CD, Muller-Gartner H, Ackermann R. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol 1999;36:582-587.

9. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:31-35.

10. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996;155:994-998.